116 related articles for article (PubMed ID: 9436478)
1. [Treatment of familial combined hyperlipidemia].
Bruckert E
Ann Endocrinol (Paris); 1997; 58(4):297-301. PubMed ID: 9436478
[No Abstract] [Full Text] [Related]
2. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Didangelos TP; Carina MV; Kranitsas DF; Kontopoulos AG
Am J Cardiol; 1997 Sep; 80(5):608-13. PubMed ID: 9294990
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
Athyros VG; Papageorgiou AA; Athyrou VV; Demitriadis DS; Pehlivanidis AN; Kontopoulos AG
J Cardiovasc Risk; 2002 Feb; 9(1):33-9. PubMed ID: 11984215
[TBL] [Abstract][Full Text] [Related]
4. Statin-fibrate combinations in patients with combined hyperlipedemia.
Athyros VG; Papageorgiou AA; Kontopoulos AG
Atherosclerosis; 2001 Mar; 155(1):263-4. PubMed ID: 11293392
[No Abstract] [Full Text] [Related]
5. The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
Schonfeld G
Atherosclerosis; 1994 Dec; 111(2):161-74. PubMed ID: 7718018
[TBL] [Abstract][Full Text] [Related]
6. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Mikhailidis DP; Jagroon IA
Metabolism; 2001 Nov; 50(11):1385-6. PubMed ID: 11715936
[No Abstract] [Full Text] [Related]
7. Drug interactions with fibric acids.
Lozada A; Dujovne CA
Pharmacol Ther; 1994 Aug; 63(2):163-76. PubMed ID: 7809177
[TBL] [Abstract][Full Text] [Related]
8. Implication of fibrate therapy for homocysteine.
Goffin E; Jamar F; Desager JP; Devuyst O
Lancet; 1999 Oct; 354(9185):1209. PubMed ID: 10513738
[No Abstract] [Full Text] [Related]
9. Drug treatment of combined hyperlipidemia.
Wierzbicki AS; Mikhailidis DP; Wray R
Am J Cardiovasc Drugs; 2001; 1(5):327-36. PubMed ID: 14728015
[TBL] [Abstract][Full Text] [Related]
10. Lipid profiles on fibric-acid derivatives.
Capps NE
Lancet; 1994 Sep; 344(8923):684-5. PubMed ID: 7915370
[No Abstract] [Full Text] [Related]
11. [The action of a fibric acid derivative on lipid metabolism].
Filip M; Păduraru I; Nechifor M; Dănilă GH; Popovici I; Filip FM; Poşircă F
Rev Med Chir Soc Med Nat Iasi; 1989; 93(3):573-6. PubMed ID: 2636755
[TBL] [Abstract][Full Text] [Related]
12. Abnormal lipid profiles on fibrate derivatives.
McLeod AJ; Warren RJ; Armitage M
Lancet; 1996 Jan; 347(8996):261. PubMed ID: 8551900
[No Abstract] [Full Text] [Related]
13. Comparative and simultaneous effects of simvastatin and ciprofibrate on plasma lipid parameters and upon hepatic drug metabolizing and peroxisome proliferation marker enzymes in the male Wistar rat.
Charmoillaux M; Goudonnet H; Mercenne F; Mounié J; Truchot RC
Cell Mol Biol; 1991; 37(8):765-71. PubMed ID: 1807786
[TBL] [Abstract][Full Text] [Related]
14. Ciprofibrate and lipid profile.
Chandler HA; Batchelor AJ
Lancet; 1994 Jul; 344(8915):128-9. PubMed ID: 7912363
[No Abstract] [Full Text] [Related]
15. [The treatment of chronic ischemic heart disease: the potentials for hypolipidemic correction using current drugs].
Tashchuk VK; Makoviĭchuk IO; Bilets'kyĭ SV; Hrechko SI; Polishchuk OIu; Turubarova NA
Lik Sprava; 1998; (5):101-3. PubMed ID: 9793321
[TBL] [Abstract][Full Text] [Related]
16. [Long-term treatment of hyperlipoproteinemia with etofibrate].
Bartz VT; Gatz J; Slotty C; Schröter C; Töle R; Wand P
Fortschr Med; 1993 Sep; 111(25):398-400. PubMed ID: 8406286
[TBL] [Abstract][Full Text] [Related]
17. [Experimental research on the action of a derivative from a p-chloropenoxyisobutyric acid series on lipid parameters].
Filip M; Hriscu A; Păduraru I; Rusu M
Rev Med Chir Soc Med Nat Iasi; 1986; 90(1):156-60. PubMed ID: 3764166
[No Abstract] [Full Text] [Related]
18. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.
Collinson PO; Hjelm CJ; Canepo-Anson R
Ann Clin Biochem; 1996 Mar; 33 ( Pt 2)():159-61. PubMed ID: 8729728
[No Abstract] [Full Text] [Related]
19. [Cytolytic hepatic damage caused by ciprofibrate].
Perault MC; Fievre JL; Dejean C; Martin A; Vandel B
Gastroenterol Clin Biol; 1992; 16(6-7):609. PubMed ID: 1526424
[No Abstract] [Full Text] [Related]
20. Drugs recently released in Belgium. Mefloquine--ciprofibrate.
Harvengt C
Acta Clin Belg; 1991; 46(2):117-9. PubMed ID: 1649529
[No Abstract] [Full Text] [Related]
[Next] [New Search]
